Enhancement of immune responses to the hepatitis B virus core protein through DNA vaccines with a DNA fragment encoding human IL-1β 163-171 peptide

Acta Virologica

Volumn 47, Issue 4, 2003, Pages 217-221

  Shao, H J ^a   Chen, L ^a   Shen, M S ^a   Yu, G F ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

DNA vaccine; Hepatitis B virus core antigen; Interleukin 1

Indexed keywords

ADJUVANT; CORE PROTEIN; DNA FRAGMENT; DNA VACCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B VIRUS CORE PROTEIN; HYBRID PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA[163-171]; UNCLASSIFIED DRUG;

ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; RECEPTOR BINDING; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; BASE SEQUENCE; DNA, RECOMBINANT; ESCHERICHIA COLI; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-1BETA; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; VACCINES, DNA;

ANIMALIA; HEPATITIS B VIRUS;

EID: 0442325260     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Antoni G, Presentini R, Perin F, Tagliabue A, Ghiara P, Censini S, Volpini G, Villa L, Boraschi D (1986): A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. J. Immunol. 137, 3201-3204.
2. Beckers W, Villa L, Gonfloni S, Castagnoli L, Newton SM, Cesareni G, Ghiara P (1993): Increasing the immunogenicity of protein antigens through the genetic insertion of VQGEESNDK sequence of human IL-1β into their sequence. J. Immunol. 151, 1757-1764.
3. Boraschi D and Tagliabue A (1999): Interleukin-1 and interleukin-1 fragments as vaccine adjuvants. Methods 19, 108-113.
4. Ciernik IF, Berzofsky JA, Carbone DP (1996): Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156, 2369-2375.
5. Dinarello CA (1992): The biology of interleukin-1. Chem. Immunol. 51, 1-32.
6. Dinarello CA (1996): Biologic basis for interleukin-1 in disease. Blood 87, 2095-2147.
7. Geissler M, Tokushige K, Wakita T, Zurawski VR Jr, Wands JR (1998): Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine 16, 857-867.
8. Kim JJ, Yang JS, Manson KH, Weiner DB (2001): Modulation of antigen-specific cellular immuneresponses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-γ, or IL-4 gene adjuvants. Vaccine 19, 2497-2505.
9. Lin R, Tarr PE, Jones TC (1995): Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin. Infect. Dis. 21, 1439-1449.
10. Lowrie DB, Silva CL, Colston MJ, Ragno S, Tascon RE (1997): Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 15, 834-838.
11. Lozes E, Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Vandenbussche P, Van Vooren JP, Drowart A, Ulmer JB, Liu MA (1997): Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 15, 830-833.
12. Manickan E, Rouse RJ, Yu Z, Wire WS, Rouse BT (1995): Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. J. Immunol. 155, 259-265.
13. Nencioni L, Villa L, Tagliabue A, Antoni G, Presentini R, Perin F, Silvestri S, Boraschi D (1987): In vivo immunostimulating activity of the 163-171 peptide of human IL-1 beta. J. Immunol. 139, 800-804.
14. Nobiron I, Thompson I, Brownlie J, Collins ME (2001): Cytikine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice. Vaccine 19, 4226-4235.
15. Rao KVS, Nayak AR (1990): Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human interlaukin 1. Proc. Natl. Acad. Sci. USA 87, 5519-5522.
16. nd ed. Cold Spring Harbor Laboratory Press.
17. Staats HF, Ennis FA Jr (1999): IL-1 is effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J. Immunol. 162, 6141-6147.
18. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE (1995): Idiotypic DNA vaccines against B-cell lymphoma. Immunol. Rev. 145, 211-228.
19. Tagliabue A, Boraschi D (1993): Cytokines as vaccine adjuvants: Interleukin 1 and its synthetic peptide 163-171. Vaccine 11(5), 594-595.
20. Tang DC, DeVit M, Johnston SA (1992): Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154.
21. Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HCJ (1994): Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199, 132-140.
22. nd (1996): Interleukin I trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Stem Cells 14, 164-176.
23. Verschraegen, CF, Kudelka AP, Termrungruanglert W, de Leon CG, Edwards CL, Freedman RS, Kavanagh JJ, Vadhan-Raj S (1996): Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease. Eur. J. Cancer 32A, 1609-1611.
24. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB (1993): Gene inoculation generates immune responses against human immunodeficiency virus type I. Proc. Natl. Acad. Sci. USA 90, 4156-4160.
25. Wang S, Liu X, Fisher K, Smith JG, Chen F, Tobery TW, Ulmer JB, Evans RK, Caufield MJ (2000): Enhanced type immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminium-phosphate. Vaccine 18, 1227-1235.
26. Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN (1998): Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 102, 1258-1264.